
The USA's Advanced Research Projects Agency for Health (ARPA-H) has selected five teams to build the equipment needed to make individualized RNA medicines close to the patient, awarding contracts worth up to $125 million in research and development funding.
The awards, announced Tuesday, come under the agency's Genetic Medicines and Individualized Manufacturing for Everyone (GIVE) program, which aims to replace today's slow and costly centralized production with an automated network able to turn out genetic medicines on demand.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze